Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2007 1
2011 3
2012 1
2015 1
2016 2
2019 1
2020 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrøm V. Leroux-Roels I, et al. Among authors: de heusch m. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327. J Infect Dis. 2023. PMID: 35904987 Free PMC article. Clinical Trial.
The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains.
Sacconnay L, De Smedt J, Rocha-Perugini V, Ong E, Mascolo R, Atas A, Vanden Abeele C, de Heusch M, De Schrevel N, David MP, Bouzya B, Stobbelaar K, Vanloubbeeck Y, Delputte PL, Mallett CP, Dezutter N, Warter L. Sacconnay L, et al. Among authors: de heusch m. Sci Transl Med. 2023 Aug 23;15(710):eadg6050. doi: 10.1126/scitranslmed.adg6050. Epub 2023 Aug 23. Sci Transl Med. 2023. PMID: 37611082
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, Banooni P, Gardener GJ, Rasero JLB, Pardilla MBE, Langley JM, Di Leo CM, Botelho-Nevers E, Buttery J, Laurichesse H, Madhi SA, García AM, Stanley T, Barjat T, Griffith R, Castrejón-Alba MM, de Heusch M, Dieussaert I, Hercor M, Lese P, Qian H, Tullio AN, Henry O. Bebia Z, et al. Among authors: de heusch m. J Infect Dis. 2023 Aug 11;228(3):299-310. doi: 10.1093/infdis/jiad024. J Infect Dis. 2023. PMID: 36722147 Free PMC article. Clinical Trial.
Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
F Schwarz T, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, Hulstrøm V. F Schwarz T, et al. Among authors: de heusch m. J Infect Dis. 2023 Dec 14:jiad546. doi: 10.1093/infdis/jiad546. Online ahead of print. J Infect Dis. 2023. PMID: 38099559
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.
Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L. Van Belle AB, et al. Among authors: de heusch m. J Immunol. 2012 Jan 1;188(1):462-9. doi: 10.4049/jimmunol.1102224. Epub 2011 Nov 30. J Immunol. 2012. PMID: 22131335
18 results